Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor versus placebo for alkaline phosphatase normalization in adults with primary biliary cholangitis
2024-510695-20-00Phase 3Completed
- Sponsor
- Ipsen
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing Elafibranor with Placebo (2 arms). Primary endpoint: Percentage of participants with normalization of alkaline phosphatase at Week 52. Started Sep 2024; status: completed.
02
Drugs
elafibranor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2024-510695-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510695-20-00.